Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
5.29
-0.52 (-8.95%)
Mar 31, 2025, 4:00 PM EDT - Market closed
Recursion Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
Cash & Equivalents | 594.35 | 391.57 | 549.91 | 285.12 | 262.13 | Upgrade
|
Short-Term Investments | - | - | - | 231.45 | - | Upgrade
|
Cash & Short-Term Investments | 594.35 | 391.57 | 549.91 | 516.56 | 262.13 | Upgrade
|
Cash Growth | 51.79% | -28.79% | 6.46% | 97.07% | 275.09% | Upgrade
|
Accounts Receivable | - | - | - | 0.03 | 0.16 | Upgrade
|
Other Receivables | 49.17 | 3.09 | 2.75 | 9.06 | - | Upgrade
|
Receivables | 49.17 | 3.09 | 2.75 | 9.09 | 0.16 | Upgrade
|
Restricted Cash | 3.05 | 3.23 | 1.28 | 1.55 | 2 | Upgrade
|
Other Current Assets | 67.71 | 40.25 | 15.87 | 7.51 | 2.16 | Upgrade
|
Total Current Assets | 714.27 | 438.14 | 569.81 | 534.72 | 266.44 | Upgrade
|
Property, Plant & Equipment | 233.21 | 120.17 | 121.45 | 64.73 | 25.97 | Upgrade
|
Goodwill | 148.87 | 52.06 | 0.8 | 0.8 | 0.8 | Upgrade
|
Other Intangible Assets | 335.86 | 36.44 | 1.31 | 1.39 | 1.69 | Upgrade
|
Long-Term Deferred Tax Assets | 1.93 | - | - | - | - | Upgrade
|
Other Long-Term Assets | 14.45 | 6.89 | 7.92 | 8.72 | 3.69 | Upgrade
|
Total Assets | 1,449 | 653.7 | 701.29 | 610.35 | 298.59 | Upgrade
|
Accounts Payable | 21.61 | 3.95 | 4.59 | 2.82 | 1.07 | Upgrade
|
Accrued Expenses | 80.28 | 41.76 | 30.29 | 27.67 | 10.49 | Upgrade
|
Current Portion of Long-Term Debt | 0.11 | 0.04 | 0.1 | 0.09 | 1.07 | Upgrade
|
Current Portion of Leases | 22.11 | 6.12 | 5.95 | - | - | Upgrade
|
Current Unearned Revenue | 61.77 | 36.43 | 56.73 | 10 | 10 | Upgrade
|
Other Current Liabilities | 1.59 | 4.87 | 2.62 | 6.08 | 0.47 | Upgrade
|
Total Current Liabilities | 187.47 | 93.17 | 100.27 | 46.66 | 23.1 | Upgrade
|
Long-Term Debt | 0.68 | 1.1 | 0.54 | 0.63 | 11.41 | Upgrade
|
Long-Term Leases | 85.59 | 43.41 | 44.42 | - | - | Upgrade
|
Long-Term Unearned Revenue | 118.77 | 51.24 | 70.26 | 6.67 | 16.67 | Upgrade
|
Long-Term Deferred Tax Liabilities | 16.58 | 1.34 | - | - | - | Upgrade
|
Other Long-Term Liabilities | 4.73 | - | - | 13.45 | 5.38 | Upgrade
|
Total Liabilities | 413.82 | 190.26 | 215.48 | 67.41 | 56.56 | Upgrade
|
Common Stock | 0 | 0 | 0 | 0 | - | Upgrade
|
Additional Paid-In Capital | 2,474 | 1,431 | 1,125 | 943.14 | 7.31 | Upgrade
|
Retained Earnings | -1,431 | -967.62 | -639.56 | -400.08 | -213.6 | Upgrade
|
Comprehensive Income & Other | -7.64 | - | - | -0.13 | - | Upgrade
|
Total Common Equity | 1,035 | 463.44 | 485.81 | 542.94 | -206.29 | Upgrade
|
Shareholders' Equity | 1,035 | 463.44 | 485.81 | 542.94 | 242.02 | Upgrade
|
Total Liabilities & Equity | 1,449 | 653.7 | 701.29 | 610.35 | 298.59 | Upgrade
|
Total Debt | 108.49 | 50.67 | 51.01 | 0.72 | 12.49 | Upgrade
|
Net Cash (Debt) | 485.86 | 340.89 | 498.91 | 515.84 | 249.64 | Upgrade
|
Net Cash Growth | 42.52% | -31.67% | -3.28% | 106.63% | 335.00% | Upgrade
|
Net Cash Per Share | 1.77 | 1.64 | 2.84 | 4.12 | 11.46 | Upgrade
|
Filing Date Shares Outstanding | 401.99 | 234.65 | 191.23 | 170.77 | 22.31 | Upgrade
|
Total Common Shares Outstanding | 396.8 | 234.27 | 191.02 | 170.27 | 22.31 | Upgrade
|
Working Capital | 526.8 | 344.97 | 469.55 | 488.06 | 243.34 | Upgrade
|
Book Value Per Share | 2.61 | 1.98 | 2.54 | 3.19 | -9.24 | Upgrade
|
Tangible Book Value | 550.05 | 374.94 | 483.7 | 540.75 | -208.78 | Upgrade
|
Tangible Book Value Per Share | 1.39 | 1.60 | 2.53 | 3.18 | -9.36 | Upgrade
|
Machinery | 128.29 | 82.22 | 67.69 | 53.08 | 20.78 | Upgrade
|
Construction In Progress | 2.71 | 3.23 | 8.75 | 16.45 | 1.36 | Upgrade
|
Leasehold Improvements | 72.73 | 45.93 | 41.87 | 13.94 | 13.79 | Upgrade
|
Updated Feb 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.